NCT02197078View on ClinicalTrials.gov

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

CompletedOBSERVATIONAL
Enrollment

189,426

Participants

Timeline

Start Date

July 30, 2014

Primary Completion Date

February 26, 2019

Study Completion Date

February 26, 2019

Conditions
Diabetes Mellitus, Type 2
Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY